US Non-oncology Biopharmaceuticals Market- Insights
Biologics are very large, complex molecules or mixture of molecules that are derived from living entities such as microorganisms and plants or animal cells. A part of biologics, biopharmaceuticals are substances developed in living systems using biotechnology. Non-oncology biopharmaceuticals are drugs used for the treatment of diseases except cancer.
U.S. Non-oncology Biopharmaceuticals Market: Drivers
Approval and launch of new biopharmaceuticals for non-oncology diseases is expected to propel growth of the U.S. non-oncology biopharmaceuticals market over the forecast period. For instance, in September 2018, Eli Lilly and Company received the U.S. Food and Drug Administration (FDA) approval for its Emgality (galcanezumab-gnlm) 120 mg injection, for the preventive treatment of migraine in adults.
U.S. Non-oncology Biopharmaceuticals Market: Restraints
High cost of branded biologics is expected to hamper growth of the U.S. non-oncology biopharmaceuticals market. For instance, according to the report published by the Association for Accessible Medicines in 2018, the annual treatment with Humira costs US$ 38,000. Moreover, according to a report published by I-Mak.org, between 2012 and 2016, the average spending on Humira per person in U.S. increased from US$ 16,000 to US$ 33,000.
U.S. Non-oncology Biopharmaceuticals Market: Opportunities
Major blockbuster drugs are expected to lose patent protection, which is expected to offer lucrative opportunity for development of biosimilars. For instance, in 2017, Merck & Co., Inc. launched RENFLEXIS (infliximab-abda), a biosimilar of the originator biologic medicine Remicade (infliximab) by Janssen Biotech, Inc., in the U.S. at a wholesaler acquisition cost of US$ 753.39, representing a 35% discount to the current list price of Remicade.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Source: Pharmi Web
